New Research Moves Us One Step Closer To Personalised Breast Cancer Treatment

Scientists have found that a test, already used in breast cancer diagnosis, can also predict who will and who won't benefit from commonly used chemotherapy drugs.
The research shows that women who have a duplication of chromosome 17 in their tumour will benefit from anthracycline drugs, while others can be spared the side-effects of the treatment. This group of chemotherapy drugs includes epirubicin which has already been shown to improve women's survival by a third.
This research is important as both the chemotherapy drugs and the test are already available, so a change in clinical practice could happen in the very near future.
The results of the British study are being presented at the San Antonio Breast Cancer Symposium today.
http://www.medicalnewstoday.com/articles/133259.php